NCT07155174
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07155174
Title A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (SEZanne)
Acronym SEZanne
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ISR

Facility Status City State Zip Country Details
Ocala Oncology Center /ID# 278269 RECRUITING Ocala Florida 34474 United States Details
Fort Wayne Medical Oncology And Hematology /ID# 277336 RECRUITING Fort Wayne Indiana 46804 United States Details
Meir Medical Center /ID# 277292 RECRUITING Kfar Saba Central District 4428164 Israel Details
Assuta Ashdod Medical Center /ID# 276661 RECRUITING Ashdod Southern District 7747600 Israel Details
The Chaim Sheba Medical Center /ID# 276660 RECRUITING Ramat Gan Tel Aviv 5265601 Israel Details
Rambam Health Care Campus /ID# 276663 RECRUITING Haifa 3525408 Israel Details
Hadassah Medical Center-Hebrew University /ID# 276662 RECRUITING Jerusalem 91120 Israel Details
Tokyo Metropolitan Komagome Hospital /ID# 277335 RECRUITING Bunkyo Ku Tokyo 113-8677 Japan Details
National Cancer Center Hospital /ID# 277237 RECRUITING Chuo-Ku Tokyo 104-0045 Japan Details
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 277267 RECRUITING Kaohsiung City 807 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field